Table 1 Oncomine Comprehensive Assay

HCT116

CTNNB1: p.S45del (c.133_135delTCT) (52,1%); PIK3CA: p.H1047R (c.3140A > G) (45,8%) NOTCH1: p.D1609_R1633del25 (c.4826_4900del75) (33,3%); KRAS: p.G13D (c.38G > A) (53,2%)

–

–

HCT116 CM-R

CTNNB1: p.S45del (c.133_135delTCT) (41%); PIK3CA: p.H1047R (c.3140A > G) (43%) NOTCH1: p.D1609_R1633del25 (c.4826_4900del75) (32%); KRAS: p.G13D (c.38G > A) (49%)

–

–

HCT 15

PIK3CA: p.E545K (c.1633G > A) (100%); KRAS: p. p.G13D (c.38G > A) (52,4%); TP53: p.S241F (c.722C > T) (49,2%)

–

–

HCT15 CM-R

PIK3CA: p.E545K (c.1633G > A) (100%); KRAS: p. p.G13D (c.38G > A) (51%); TP53: p.S241F (c.722C > T) (48%)

–

–

LoVo

FBXW7: p.R505C (c.1513C > T) (45%); KRAS: p. p.G13D (c.38G > A) (69%);

–

–

LoVo CM-R

FBXW7: p.R505C (c.1513C > T) (49,6%); KRAS: p. p.G13D (c.38G > A) (78%);

–

–